Genetic screening for cystic fibrosis: An overview of the science and the economics

Journal of Cystic Fibrosis

Volumn 6, Issue 4, 2007, Pages 255-261

  Brice, Philippa ^a   Jarrett, James ^a,b   Mugford, Miranda ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; ECONOMIC EVALUATION; GENE TECHNOLOGY; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; MASS SCREENING; MUTATIONAL ANALYSIS; NEWBORN SCREENING; PRENATAL SCREENING; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; REVIEW;

COSTS AND COST ANALYSIS; CYSTIC FIBROSIS; GENETIC SCREENING; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 34250810752     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2007.02.002     Document Type: Review

References (39)

1. Murray J., Cuckle H., Taylor G., Littlewood J., and Hewison J. Screening for cystic fibrosis. Health Technol Assess 3 (1999) 1-104
2. Turcios N.L. Cystic fibrosis: an overview. J Clin Gastroenterol 39 4 (2005) 307-317
3. Estivill X., Bancells C., and Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 10 2 (1997) 135-154
4. McKone E.F., Emerson S.S., Edwards K.L., and Aitken M.L. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361 (2003) 1671-1676
5. Cuppens H., Lin W., Jaspers M., Costes B., Teng H., Vankeerberghen A., et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101 2 (Jan 15 1998) 487-496
6. Groman J.D., Hefferon T.W., Casals T., Bassas L., Estivill X., Des Georges M., et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 74 (2004) 176-179
7. Bradley L.A., and Lubin I. Carrier testing for cystic fibrosis: transition from research to clinical practice. Chapter 9, Genomics and Population Health: United States (2003), Centers for Disease Control and Prevention, Office of Genomics and Disease Prevention. http://www.cdc.gov/genomics/activities/ogdp/2003.htm Available from http://www.cdc.gov/genomics/activities/ogdp/2003.htm
8. Franklin CR, LeGrave D, York M, Entwistle TD, Strom CM. Reporting the CFTR intron 8 5T allele in general population screening: muddying the waters. [abstract]. Annual Clinical Genetics Meeting Program and Abstracts, March 13-16, 2003, San Diego, CA; sponsored and accredited by the American College of Medical Genetics:68.
9. Hamilton J. Genetic tests for cystic fibrosis raise concerns. National Public Radio. 2003 April 4;Morning Edition. Transcript available at: http://discover.npr.org/features/feature.jhtml?wfId=1219425. Accessed November 22nd, 2006.
10. ten Kate L.P. Carrier screening for cystic fibrosis and other autosomal recessive diseases. Am J Hum Genet 47 2 (1990) 359-361
11. Merelle M.E., Lees C.M., Nagelkerke A.F., and Dezateux C. Newborn screening for cystic fibrosis. Cochrane Database Syst Rev (2000) CD001402
12. Lai H.J., Cheng Y., and Farrell P.M. The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J Pediatr 147 3 Suppl (2005) S57-S63
13. Dankert-Roelse J.E., and Merelle M.E. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr 147 3 Suppl (2005) S15-S20
14. Grosse S.D., Rosenfeld M., Devine O.J., Lai H.J., and Farrell P.M. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 149 3 (2006) 362-366
15. Sims E.J., McCormick J., Mehta G., and Mehta A. Steering Committee of the UK Cystic Fibrosis Database. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr 147 3 Suppl (Sep 2005) S42-S46
16. Farrell M.H., and Farrell P.M. Newborn screening for cystic fibrosis: ensuring more good than harm. Pediatrics 143 (2003) 707-712
17. Wilfond B.S., Parad R.B., and Fost N. Balancing benefits and risks for cystic fibrosis newborn screening: implications for policy decisions. J Pediatr 147 3 Suppl (2005) S109-S113
18. McCormick J., Green M.W., Mehta G., Culross F., and Mehta A. Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet 10 10 (2002) 583-590
19. Kabra S.K., Kabra M., Shastri S., and Lodha R. Diagnosing and managing cystic fibrosis in the developing world. Paediatr Respir Rev 7 Suppl 1 (2006) S147-S150
20. Lakeman P., Henneman L., Bezemer P.D., Cornel M.C., and ten Kate L.P. Developing and optimizing a decisional instrument using self-reported ancestry for carrier screening in a multi-ethnic society. Genet Med 8 8 (2006) 502-509
21. Bobadilla J.L., Macek Jr. M., Fine J.P., and Farrell P.M. Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 19 6 (2002) 575-606
22. Jarrett J., and Mugford M. Genetic health technologies and economic evaluations: a critical review. Appl Health Econ Health Policy 5 1 (2006) 27-35
23. Baumann U., Stocklossa C., Greiner W., von der Schulenburg J.M., and von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2 2 (Jun 2003) 84-90
24. Robson M., Abbott J., Webb K., Dodd M., and Walsworth-Bell J. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 47 9 (Sep 1992) 684-689
25. Wildhagen M.F., Hilderink H.B., Verzijl J.G., Verheij J.B., Kooij L., Tijmstra T., et al. Costs, effects, and savings of screening for cystic fibrosis gene carriers. J Epidemiol Community Health 52 (1998) 459-467
26. Lieu T.A., Watson S.E., and Washington A.E. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 84 6 (Dec 1994) 903-912
27. Cuckle H.S., Richardson G.A., Sheldon T.A., and Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 311 (1995) 1460-1464
28. Vintzileos A.M., Ananth C.V., Smulian J.C., Fisher A.J., Day-Salvatore D., and Beazoglou T. A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 91 (1998) 529-534
29. Rowley P.T., Loader S., and Kaplan R.M. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet 63 (1998) 1160-1174
30. van den Akker-van Marle M.E., Dankert H.M., Verkerk P.H., and Dankert-Roelse J.E. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 118 3 (Sep 2006) 896-905
31. Asch D.A., Hershey J.C., Pauly M.V., Patton J.P., Jedrziewski M.K., and Mennuti M.T. Genetic screening for reproductive planning: methodological and conceptual issues in policy analysis. Am J Public Health 86 (1996) 684-690
32. Nielsen R., and Gyrd-Hansen D. Prenatal screening for cystic fibrosis: an economic analysis. Health Econ 11 (2002) 285-299
33. Doran C., and Vos T. Cost effectiveness analysis in cystic fibrosis. J Cyst Fibros 4 (2005) 211-212
34. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
35. Drummond M., O'Brien B., Stoddart G., and Torrance G. Methods for the economic evaluation of health care programmes (1987), Oxford university Press, Oxford
36. Garrison L. The ISPOR good practice modeling principles-a sensible approach: be transparent, be reasonable. Value Health 6 (2003) 6-8
37. Donaldson C., Shackley P., and Abdalla M. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 6 2 (Mar-Apr 30 1997) 145-159
38. Ryan M., and Gerard K. Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2 1 (2003) 55-64
39. Louviere J.J., Hensher D.A., and Swait J.D. Stated choice methods: analysis and applications (2000), Cambridge University Press, Cambridge, UK, New York